APA (7th ed.) Citation

Roderburg, C., Gonzalez Carmona, M., Berres, M., Modest, D., Mohr, R., Wree, A., . . . Kehmann, L. (2025). 321P Results of an open-label, single-arm phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second-line therapy in patients with cholangiocarcinoma (TRITICC). Annals of Oncology, 36, S125. https://doi.org/10.1016/j.annonc.2025.05.336

Chicago Style (17th ed.) Citation

Roderburg, C., et al. "321P Results of an Open-label, Single-arm Phase II Trial Investigating the Efficacy and Safety of Trifluridine/tipiracil Combined with Irinotecan as a Second-line Therapy in Patients with Cholangiocarcinoma (TRITICC)." Annals of Oncology 36 (2025): S125. https://doi.org/10.1016/j.annonc.2025.05.336.

MLA (9th ed.) Citation

Roderburg, C., et al. "321P Results of an Open-label, Single-arm Phase II Trial Investigating the Efficacy and Safety of Trifluridine/tipiracil Combined with Irinotecan as a Second-line Therapy in Patients with Cholangiocarcinoma (TRITICC)." Annals of Oncology, vol. 36, 2025, p. S125, https://doi.org/10.1016/j.annonc.2025.05.336.